http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 26 Aug 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+to+Participate+in+the+Wells+Fargo+21st+Annual+Healthcare+Conference/26977505.html <p>RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8-10, 2026.</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td colspan="2"><strong>Wells Fargo 21st Annual Healthcare Conference</strong></td></tr><tr><td style="max-width:15%; width:15%; min-width:15%;">Date:</td><td style="max-width:85%; width:85%; min-width:85%;">Wednesday, September 9, 2026</td></tr><tr><td>Time:</td><td>4:30pm EDT</td></tr><tr><td>Format:</td><td>Fireside Chat</td></tr><tr><td>Webcast Link:</td><td><a target="_blank" href="https://event.summitcast.com/view/aMepMFxWv3z5SRZ9meKJzp/guest_book?session_id=g7cPcjcTE79NVVLPdPN82c" rel="nofollow" target="_blank">Click Here</a></td></tr><tr><td> </td><td> </td></tr></table> <p>A http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+to+Participate+in+the+Wells+Fargo+21st+Annual+Healthcare+Conference/26977505.html Wed, 26 Aug 2026 08:00:00 -0400 MLYS O.50481249 http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+to+Participate+in+the+Wells+Fargo+21st+Annual+Healthcare+Conference/26977505.html <p>RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8-10, 2026.</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td colspan="2"><strong>Wells Fargo 21st Annual Healthcare Conference</strong></td></tr><tr><td style="max-width:15%; width:15%; min-width:15%;">Date:</td><td style="max-width:85%; width:85%; min-width:85%;">Wednesday, September 9, 2026</td></tr><tr><td>Time:</td><td>4:30pm EDT</td></tr><tr><td>Format:</td><td>Fireside Chat</td></tr><tr><td>Webcast Link:</td><td><a target="_blank" href="https://event.summitcast.com/view/aMepMFxWv3z5SRZ9meKJzp/guest_book?session_id=g7cPcjcTE79NVVLPdPN82c" rel="nofollow" target="_blank">Click Here</a></td></tr><tr><td> </td><td> </td></tr></table> <p>A http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+to+Participate+in+the+Wells+Fargo+21st+Annual+Healthcare+Conference/26977505.html Wed, 26 Aug 2026 08:00:00 -0400 MLYS O.50481249 http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+to+Participate+in+the+Wells+Fargo+21st+Annual+Healthcare+Conference/26977505.html <p>RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8-10, 2026.</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td colspan="2"><strong>Wells Fargo 21st Annual Healthcare Conference</strong></td></tr><tr><td style="max-width:15%; width:15%; min-width:15%;">Date:</td><td style="max-width:85%; width:85%; min-width:85%;">Wednesday, September 9, 2026</td></tr><tr><td>Time:</td><td>4:30pm EDT</td></tr><tr><td>Format:</td><td>Fireside Chat</td></tr><tr><td>Webcast Link:</td><td><a target="_blank" href="https://event.summitcast.com/view/aMepMFxWv3z5SRZ9meKJzp/guest_book?session_id=g7cPcjcTE79NVVLPdPN82c" rel="nofollow" target="_blank">Click Here</a></td></tr><tr><td> </td><td> </td></tr></table> <p>A http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+to+Participate+in+the+Wells+Fargo+21st+Annual+Healthcare+Conference/26977505.html Wed, 26 Aug 2026 08:00:00 -0400 MLYS O.50481249 http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+to+Participate+in+the+Wells+Fargo+21st+Annual+Healthcare+Conference/26977505.html <p>RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8-10, 2026.</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td colspan="2"><strong>Wells Fargo 21st Annual Healthcare Conference</strong></td></tr><tr><td style="max-width:15%; width:15%; min-width:15%;">Date:</td><td style="max-width:85%; width:85%; min-width:85%;">Wednesday, September 9, 2026</td></tr><tr><td>Time:</td><td>4:30pm EDT</td></tr><tr><td>Format:</td><td>Fireside Chat</td></tr><tr><td>Webcast Link:</td><td><a target="_blank" href="https://event.summitcast.com/view/aMepMFxWv3z5SRZ9meKJzp/guest_book?session_id=g7cPcjcTE79NVVLPdPN82c" rel="nofollow" target="_blank">Click Here</a></td></tr><tr><td> </td><td> </td></tr></table> <p>A http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+to+Participate+in+the+Wells+Fargo+21st+Annual+Healthcare+Conference/26977505.html Wed, 26 Aug 2026 08:00:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Aug+21++Filed+by%3A+Warren+Eric/26975717.html si-local-file:///var/storage/secattach/20260825/26975717.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Aug+21++Filed+by%3A+Warren+Eric/26975717.html Tue, 25 Aug 2026 17:17:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Aug+21++Filed+by%3A+Warren+Eric/26975717.html si-local-file:///var/storage/secattach/20260825/26975717.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Aug+21++Filed+by%3A+Warren+Eric/26975717.html Tue, 25 Aug 2026 17:17:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Warren+Eric/26961568.html si-local-file:///var/storage/secattach/20260821/26961568.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Warren+Eric/26961568.html Fri, 21 Aug 2026 16:14:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Warren+Eric/26961568.html si-local-file:///var/storage/secattach/20260821/26961568.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Warren+Eric/26961568.html Fri, 21 Aug 2026 16:14:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Rodman+David+Malcom/26938493.html si-local-file:///var/storage/secattach/20260817/26938493.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Rodman+David+Malcom/26938493.html Mon, 17 Aug 2026 16:39:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Rodman+David+Malcom/26938493.html si-local-file:///var/storage/secattach/20260817/26938493.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Rodman+David+Malcom/26938493.html Mon, 17 Aug 2026 16:39:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Rodman+David+Malcom/26921193.html si-local-file:///var/storage/secattach/20260813/26921193.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Rodman+David+Malcom/26921193.html Thu, 13 Aug 2026 16:13:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Rodman+David+Malcom/26921193.html si-local-file:///var/storage/secattach/20260813/26921193.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Mineralys+Therapeutics%2C++++++++++++++++Filed+by%3A+Rodman+David+Malcom/26921193.html Thu, 13 Aug 2026 16:13:00 -0400 MLYS O.50481249 http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+Reports+Inducement+Award+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26920785.html <p>RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on August 10, 2026, a majority of the independent directors of Mineralys’ Board of Directors granted an inducement stock option award covering 135,000 shares and an inducement restricted stock unit award covering 102,400 shares of Mineralys common stock to Dr. Terry Ferguson, Mineralys’ newly appointed Chief Medical Officer.</p> <p>The http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+Reports+Inducement+Award+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26920785.html Thu, 13 Aug 2026 16:05:00 -0400 MLYS O.50481249 http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+Reports+Inducement+Award+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26920785.html <p>RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on August 10, 2026, a majority of the independent directors of Mineralys’ Board of Directors granted an inducement stock option award covering 135,000 shares and an inducement restricted stock unit award covering 102,400 shares of Mineralys common stock to Dr. Terry Ferguson, Mineralys’ newly appointed Chief Medical Officer.</p> <p>The http://www.streetinsider.com/Press+Releases/Mineralys+Therapeutics+Reports+Inducement+Award+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26920785.html Thu, 13 Aug 2026 16:05:00 -0400 MLYS O.50481249 http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+Reports+Inducement+Award+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26920785.html <p>RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on August 10, 2026, a majority of the independent directors of Mineralys’ Board of Directors granted an inducement stock option award covering 135,000 shares and an inducement restricted stock unit award covering 102,400 shares of Mineralys common stock to Dr. Terry Ferguson, Mineralys’ newly appointed Chief Medical Officer.</p> <p>The http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+Reports+Inducement+Award+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26920785.html Thu, 13 Aug 2026 16:05:00 -0400 MLYS O.50481249 http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+Reports+Inducement+Award+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26920785.html <p>RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on August 10, 2026, a majority of the independent directors of Mineralys’ Board of Directors granted an inducement stock option award covering 135,000 shares and an inducement restricted stock unit award covering 102,400 shares of Mineralys common stock to Dr. Terry Ferguson, Mineralys’ newly appointed Chief Medical Officer.</p> <p>The http://www.streetinsider.com/Globe+Newswire/Mineralys+Therapeutics+Reports+Inducement+Award+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26920785.html Thu, 13 Aug 2026 16:05:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Aug+10++Filed+by%3A+Rodman+David+Malcom/26914804.html si-local-file:///var/storage/secattach/20260812/26914804.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Aug+10++Filed+by%3A+Rodman+David+Malcom/26914804.html Wed, 12 Aug 2026 19:33:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Aug+10++Filed+by%3A+Rodman+David+Malcom/26914804.html si-local-file:///var/storage/secattach/20260812/26914804.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Aug+10++Filed+by%3A+Rodman+David+Malcom/26914804.html Wed, 12 Aug 2026 19:33:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Mineralys+Therapeutics%2C+++For%3A+Aug+10++Filed+by%3A+Ferguson+James+J.+III/26914805.html si-local-file:///var/storage/secattach/20260812/26914805.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Mineralys+Therapeutics%2C+++For%3A+Aug+10++Filed+by%3A+Ferguson+James+J.+III/26914805.html Wed, 12 Aug 2026 19:33:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Mineralys+Therapeutics%2C+++For%3A+Aug+10++Filed+by%3A+Ferguson+James+J.+III/26914805.html si-local-file:///var/storage/secattach/20260812/26914805.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Mineralys+Therapeutics%2C+++For%3A+Aug+10++Filed+by%3A+Ferguson+James+J.+III/26914805.html Wed, 12 Aug 2026 19:33:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Aug+10++Filed+by%3A+Ferguson+James+J.+III/26914806.html si-local-file:///var/storage/secattach/20260812/26914806.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Aug+10++Filed+by%3A+Ferguson+James+J.+III/26914806.html Wed, 12 Aug 2026 19:33:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Aug+10++Filed+by%3A+Ferguson+James+J.+III/26914806.html si-local-file:///var/storage/secattach/20260812/26914806.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mineralys+Therapeutics%2C+++For%3A+Aug+10++Filed+by%3A+Ferguson+James+J.+III/26914806.html Wed, 12 Aug 2026 19:33:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Mineralys+Therapeutics%2C+++For%3A+Jun+30/26907103.html si-local-file:///var/storage/secattach/20260811/26907103.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Mineralys+Therapeutics%2C+++For%3A+Jun+30/26907103.html Tue, 11 Aug 2026 17:19:00 -0400 MLYS O.50481249 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Mineralys+Therapeutics%2C+++For%3A+Jun+30/26907103.html si-local-file:///var/storage/secattach/20260811/26907103.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Mineralys+Therapeutics%2C+++For%3A+Jun+30/26907103.html Tue, 11 Aug 2026 17:19:00 -0400 MLYS O.50481249 http://www.streetinsider.com/Earnings/Mineralys+Therapeutics%2C+Inc.+%28MLYS%29+Misses+Q2+EPS+by+22c/26905925.html <p>Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q2 EPS of ($2.85), $0.22 worse than the analyst estimate of ($2.63).</p><p>For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) <a href="http://www.streetinsider.com/ec_earnings.php?q=MLYS">click here</a>.</p> http://www.streetinsider.com/Earnings/Mineralys+Therapeutics%2C+Inc.+%28MLYS%29+Misses+Q2+EPS+by+22c/26905925.html Tue, 11 Aug 2026 16:16:00 -0400 MLYS